Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

FET- PET RANO for Radiotherapy Assessment of Gliomas

Version 1 : Received: 2 February 2024 / Approved: 5 February 2024 / Online: 5 February 2024 (13:28:25 CET)

How to cite: Zarębska, I.; Harat, M. FET- PET RANO for Radiotherapy Assessment of Gliomas. Preprints 2024, 2024020274. https://doi.org/10.20944/preprints202402.0274.v1 Zarębska, I.; Harat, M. FET- PET RANO for Radiotherapy Assessment of Gliomas. Preprints 2024, 2024020274. https://doi.org/10.20944/preprints202402.0274.v1

Abstract

Conventional MRI sequences are standard methods to monitor patients with brain tumors but have significant limitations especially after irradiation. Currently, the role of FET-PET in radiotherapy of glioblastoma is emerging, starting from target definition, response assessment and in distinguishing progression from post-irradiation changes. Recently a PET RANO criteria have been published providing optimal strategy for treatment evaluation with amino-acid PET. Earlier, a PET/RANO group reported contribution of PET imaging to radiotherapy planning and monitoring in glioma patients. Also, increasing evidence have showed advantages of amino-acid PET vs. RANO MRI for prediction of overall survival. In this narrative review we aimed to summarize published data on FET-PET based treatment response assessment to radiotherapy and focused on details in protocols.

Keywords

glioblastoma, amino acid PET, post-treatment changes, tumor progression, response assessment

Subject

Medicine and Pharmacology, Oncology and Oncogenics

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.